Jan Stahlberg Expands Stake in DiaMedica Therapeutics with Major Purchase

Major shareholder Jan Stahlberg has significantly increased his investment in DiaMedica Therapeutics, Inc. (NASDAQ: DMAC) by acquiring 59,788 shares on August 22, 2023. The shares were purchased at an average price of $5.96 each, amounting to a total transaction value of $356,336.48. Following this acquisition, Stahlberg now holds 7,315,780 shares in the company, which are valued at approximately $43,602,048.80. This transaction reflects a 0.82% increase in his ownership position.

The transaction was disclosed in a filing with the Securities and Exchange Commission (SEC), as mandated for major shareholders owning at least 10% of a company’s shares. Such disclosures are critical for maintaining transparency within the market.

Stock Performance and Market Position

On the same day as the transaction, DiaMedica Therapeutics opened at $6.14. The stock has shown notable fluctuations, with a 50-day moving average price of $4.84 and a 200-day moving average price of $4.55. With a market capitalization of $317.38 million, the firm currently holds a negative price-to-earnings (P/E) ratio of -8.90 and a beta of 1.40. Over the past year, the stock has reached a low of $3.19 and a high of $6.82.

Institutional Investment Insights

Several institutional investors have recently altered their holdings in DiaMedica Therapeutics, reflecting growing interest in the company. For instance, Dimensional Fund Advisors LP increased its stake by 14.0% during the fourth quarter, now owning 19,339 shares valued at $105,000 after purchasing an additional 2,380 shares.

Similarly, BNP Paribas Financial Markets raised its stake by 24.4% in the second quarter, acquiring 3,709 shares to reach a total of 18,882 shares, valued at $74,000. Other notable increases include World Investment Advisors, which raised its position by 17.0%, and Bank of America Corp DE, which grew its position by an astonishing 3,710.3%, now holding 8,497 shares worth $33,000.

Institutional investors and hedge funds currently own 10.12% of DiaMedica’s stock, indicating a solid base of support from larger financial entities.

Analysts’ Perspectives and Future Outlook

Research firms have begun to set new price targets for DiaMedica Therapeutics, reflecting varied confidence levels among analysts. HC Wainwright reaffirmed a “buy” rating with a target price of $12.00 as of August 15, while Craig Hallum raised its target from $8.00 to $11.00 in a report published on July 18. Conversely, Wall Street Zen downgraded the stock from a “hold” rating to a “sell” rating earlier this week.

In contrast, Lake Street Capital increased its price objective from $11.00 to $14.00, maintaining a “buy” rating. The consensus among analysts indicates a general positive sentiment, with an average rating of “Buy” and a target price of $12.33, according to data from MarketBeat.

About DiaMedica Therapeutics

Founded as a clinical-stage biopharmaceutical company, DiaMedica Therapeutics focuses on developing treatments for serious diseases, particularly acute ischemic stroke. Its lead candidate, DM199, is a recombinant form of the human tissue kallikrein-1 protein that is currently undergoing Phase II/III trials for acute ischemic stroke and Phase II trials for cardio-renal disease.

As the company progresses with its clinical trials and receives ongoing interest from both institutional investors and analysts, its future developments will be closely monitored by market participants.